Surgical therapy in advanced heart failure
Section snippets
Heart transplantation
Heart transplantation remains the most effective therapy for end-stage heart disease.8 After the introduction of new immunosuppressive drugs, Stanford University reported a considerable improvement in heart transplantation survival results from 41% to 68% and from 24% to 46% after 5 and 10 years, respectively.9
From 1985 to 2001 at the A. De Gasperis Department of Cardiac Surgery heart transplant program (which was started during the cyclosporine-based immunosuppression era), 610 patients
Alternative surgical options
The issues summarized above, along with the biomedical improvements and the progress of surgical and intensive care strategies, have led to interest in different surgical options for the treatment of patients with end-stage heart disease. Apart from the extension of indications for conventional surgery in patients with severe left ventricular dysfunction and CHF, great progress has been made in the development of new surgical approaches including (1) left ventricular reconstruction procedures;
End-stage cardiomyopathy and coronary revascularization
The most common cause of CHF in the developed world is coronary disease. For those on the waiting list at our center, the incidence of ischemic cardiomyopathy is 55.5%. For many years, the role of coronary artery bypass grafting (CABG) has not been well defined in this group of patients. According to the Coronary Artery Surgery Study (CASS), the results of CABG in patients in the 1980s with severe left ventricular dysfunction and CHF were not encouraging.16 Great progress has been made over the
Mitral valve repair
Mitral valve incompetence is functional when the patient has a mitral regurgitation along with global systolic dysfunction of the left ventricle without structural alterations of leaflets and subvalvular apparatus.27 The clinical relevance of functional mitral incompetence in patients with CHF depends primarily on quality of life and overall prognosis. The pathogenetic hypothesis of functional mitral valve incompetence relies on geometric remodeling of the left ventricle with “misalignment” of
Ventricular assist device as a bridge to transplantation
The mechanical assist device aims to achieve an appropriate cardiac output in patients with end-stage heart disease who are not suited for conventional medical and surgical treatment. The clinical use of VAD started in the 1960s in patients with acute heart failure. In 1969, Cooley et al34 successfully applied, for the first time, an assist device as a bridge to heart transplantation, opening a new era in cardiac surgery. Since the 1980s, technologic advances have resulted in the development of
Conclusions
In the absence of a definitive cure for the treatment of the primary disease that leads to CHF, combined medical and surgical therapy will continue to be the standard of care.39 Heart transplantation is still the most successful option for such patients, but it is limited by inadequate supply of organs. Increasing use of mechanical assist systems has been suggested in patients with end-stage heart disease as a bridge to heart transplantation, to recovery, or to permanent application.
Left
References (41)
- et al.
Congestive heart failure: current controversies and future prospects
Am J Cardiol
(1990) - et al.
Prevalence and mortality rate of congestive heart failure in the United States
J Am Coll Cardiol
(1992) - et al.
Thirty years of cardiac transplantation at Stanford University
J Thorac Cardiovasc Surg
(1999) - et al.
The registry of the International Society for Heart and Lung Transplantation: sixteenth official report 1999
J Heart Lung Transplant
(1999) - et al.
Predicting long-term functional results after myocardial revascularization in ischemic cardiomyopathy
J Thorac Cardiovasc Surg
(2000) - et al.
Results of coronary artery bypass grafting by a single surgeon in patients with left ventricular ejection fraction ≤30%
Am J Cardiol
(1997) - et al.
Coronary artery bypass grafting for ischemic heart failure: the predictive value of quantitative PET for symptomatic and functional outcome
J Thorac Cardiovasc Surg
(1998) - et al.
Long-term survival of patients with coronary artery disease and left ventricular dysfunction: implications for the role of myocardial viability assessment in management decisions
J Thorac Cardiovasc Surg
(1998) - et al.
Nontransplant cardiac surgery for end-stage cardiomyopathy
J Thorac Cardiovasc Surg
(2000) - et al.
Value of transthoracic two-dimensional echocardiography in predicting viability in patients with healed Q-wave anterior wall myocardial infarction
Am J Cardiol
(1995)